SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-022611
Filing Date
2022-08-15
Accepted
2022-08-15 08:31:19
Documents
69
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1233544
2 ex4-1.htm EX-4.1 124595
3 ex10-1.htm EX-10.1 246977
4 ex31-1.htm EX-31.1 18245
5 ex31-2.htm EX-31.2 18445
6 ex32-1.htm EX-32.1 7463
7 ex32-2.htm EX-32.2 7417
  Complete submission text file 0001493152-22-022611.txt   7460958

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE mymd-20220630.xsd EX-101.SCH 56627
9 XBRL CALCULATION FILE mymd-20220630_cal.xml EX-101.CAL 48131
10 XBRL DEFINITION FILE mymd-20220630_def.xml EX-101.DEF 256865
11 XBRL LABEL FILE mymd-20220630_lab.xml EX-101.LAB 469784
12 XBRL PRESENTATION FILE mymd-20220630_pre.xml EX-101.PRE 359367
63 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1224240
Mailing Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205 856-848-8698
MyMD Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36268 | Film No.: 221162559
SIC: 2835 In Vitro & In Vivo Diagnostic Substances